Amiselimod

Synonyms: MT-1303
Amiselimod (MT-1303) 在体内通过鞘氨醇激酶转化为其活性磷酸代谢产物 Amiselimod phosphate,是一种具有口服活性、高选择性的鞘氨醇 1-磷酸受体 1 (S1P1) 激动剂,旨在减少与芬戈莫德和其他 S1P 受体调节剂相关的心动过缓效应,它通过抑制致结肠炎 Th1 和 Th17 细胞浸润结肠来抑制慢性结肠炎,通过减少自身反应性 T 细胞浸润肾脏来抑制狼疮肾炎,并有望用于自身免疫性疾病的研究。
产品编号: MS-W15596 CAS No.: 942399-20-4 分子式: C19H30F3NO3 分子量: 377.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Amiselimod (MT-1303) 在体内通过鞘氨醇激酶转化为其活性磷酸代谢产物 Amiselimod phosphate,是一种具有口服活性、高选择性的鞘氨醇 1-磷酸受体 1 (S1P1) 激动剂,旨在减少与芬戈莫德和其他 S1P 受体调节剂相关的心动过缓效应,它通过抑制致结肠炎 Th1 和 Th17 细胞浸润结肠来抑制慢性结肠炎,通过减少自身反应性 T 细胞浸润肾脏来抑制狼疮肾炎,并有望用于自身免疫性疾病的研究。

生物实验数据

生物活性 Amiselimod (MT-1303) is converted in vivo by sphingosine kinase to its active phosphate metabolite Amiselimod phosphate; it is an orally active, highly selective sphingosine 1-phosphate receptor 1 (S1P1) agonist designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators, suppresses chronic colitis by inhibiting the infiltration of colitogenic Th1 and Th17 cells into the colon, suppresses lupus nephritis by reducing the infiltration of autoreactive T cells into the kidney, and holds promise for the study of autoimmune diseases.
体外研究
(In Vitro)

Amiselimod (100 nM, 12 h) 在 HEK293 细胞或原代 HCMs (人类心肌细胞) 中转化为Amiselimod-P 的速度比 Fingolimod (MS-N91571) 转化为 fingolimod-P 的速度慢。 Amiselimod-P (0.001-1000 nM) 在人 S1P1 受体表达细胞中表现出 S1P1 受体激动剂活性, EC50 为 75 pM, 其活性高于在 S1P4 和 S1P5 受体上的活性,但在 S1P2 或 S1P3 受体上没有明显的激动剂活性。
Amiselimod-P (0.001-1000 nM) 在人类心房肌细胞中以浓度依赖的方式增加 G 蛋白激活的内向整流钾通道(GIRK) 电流幅度,其 EC50 值为 41.6 nM。

体内研究
(In Vivo)

Amiselimod (p.o., 1 mg/kg) hydrochloride 在大鼠心脏组织中转化为 Amiselimod-P 的浓度低于 fingolimod-P,这可能是其对心脏影响较小的原因。
Amiselimod (p.o., 1 mg/kg, 对照组和 0.3 mg/kg 之间间隔 6 天,剂量水平为 0.3、3 和 30 mg/kg 之间间隔 13 或 14 天) 在猴子体内对心率或心电图参数没有影响。
Amiselimod (0.3 mg/kg, p.o., 每日一次, 连续 3 天) 可降低 C57BL/6 小鼠 肠系膜淋巴结 CD4+ 细胞上 S1P1 的表达。
. Amiselimod (0.3 mg/kg, p.o., 每日一次, 连续 28 天) 抑制由CD4+CD45RBhighT 细胞过继转移诱导 SCID 小鼠结肠炎的发展。
Amiselimod (0.3 mg/kg, p.o., 每日一次, 持续 3-4 周) 减少了 Th1 和 Th17 细胞向由CD4+CD45RB high T 细胞过继转移诱导结肠炎小鼠结肠的浸润。
Amiselimod (0.1-0.3 mg/kg, p.o., 每日一次, 连续 21 天) 抑制慢性结肠炎的发展,与抗mTNF-αmAb (250 μg/只小鼠) 在过继转移 CD4+ CD45RBhighT 细胞诱导的结肠炎小鼠中的效果相当。
Amiselimod (0.1-1 mg/kg, p.o., 每日一次, 连续 18 周) 显著抑制 MRL/lpr 小鼠狼疮性肾炎的发展。
Amiselimod (0.1-0.3 mg/kg, p.o., 每日一次, 连续 10 周) 可阻止 NZBWF1 小鼠狼疮性肾炎的进展。
Amiselimod (0.3 mg/kg, p.o., 每日一次, 连续 13 周) 减少 T 细胞向 NZBWF1 小鼠肾脏的浸润。

Animal Model: Four male cynomolgus monkeys, Macaca fascicularis, 3-4 years old.
Dosage: 0.3, 3, 30 mg/kg
Administration: p.o., with a 6 day interval between vehicle and 0.3 mg/kg, 13 or 14 day intervals between dose levels of 0.3, 3 and 30 mg/kg.
Result: Had no effects on heart rate or ECG parameters, including PR interval, QRS duration, QT interval and QTc at doses up to 30 mg/kg
Did not affect blood pressure at doses up to 30 mg/kg.
Animal Model: Male C57BL/6 mice, aged 5 weeks.
Dosage: 0.3 mg/kg
Administration: p.o., daily, 3 days
Result: Decreased S1P1 expression on CD4+ T cells from mesenteric lymph nodes.
Animal Model: Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice.
Dosage: 0.1, 0.3 mg/kg
Administration: p.o., daily, 28 days
Result: Body weight remained higher than that in the control group from 4 days after cell transfer.
Body weight in the 0.3 mg/kg treated group was significantly higher than that in the control group from 17 days.
Clinical scores (sum of scores for hunching, wasting, colon thickening, and stool consistency) in the 0.1 and 0.3 mg/kg treated groups were 1.5 and 1.1.
Reduced inflammatory cell infiltrates, epithelial hyperplasia and mucin depletion from goblet cells in the colon at 0.3 mg/kg.
Animal Model: Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice.
Dosage: 0.1, 0.3 mg/kg
Administration: p.o., daily, 21 days, the anti-mTNF-α mAb (250 μg/mouse) was intraperitoneally injected on days 7 and 21.
Result: Increased body weight from day 15 comparable to anti-mTNF-α mAb-treated groups.
Clinical scores in the 0.1 and 0.3 mg/kg treated groups were 1.1 and 0.6 and anti-mTNF-α mAb-treated group was 1.2.
Inhibited the development of chronic colitis with an efficacy comparable to that of an anti-mTNF-α mAb (250 μg/mouse).
Animal Model: Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice.
Dosage: 0.3 mg/kg
Administration: p.o., daily, 3-4 weeks
Result: Significantly reduced the number of infiltrating lymphocytes and CD4+ T cells.
Decreased the number of IFN-γ- and IL-17-producing CD4+ T cells in the lamina propria.
Produced significantly less IFN-γ and IL-17 than those from vehicle-treated mice.
Animal Model: MRL/lpr mice at 8 weeks of age without proteinuria.
Dosage: 0.1, 0.3, 1 mg/kg
Administration: p.o., daily, 18 weeks
Result: No mice treated at doses greater than 0.3 mg/kg developed lupus nephritis during the study period.
Reduced this infiltration of T cells into the kidneys.
Inhibited the development of lymphadenopathy and splenomegaly.
Decreased the number of T cells,CD4 T cells, B cells, and MRL/lpr-mouse-specific abnormal T cells.
Animal Model: NZBWF1 mice at 30 weeks of age without proteinuria.
Dosage: 0.1, 0.3 mg/kg
Administration: p.o., daily, 10 weeks
Result: Mean proteinuria scores remained lower than those in the control group.
Attenuated the severity of several histological changes including mesangial expansion, glomerular sclerosis, and interstitial infiltrates.
Animal Model: NZBWF1 mice at 41 weeks of age without proteinuria.
Dosage: 0.3 mg/kg
Administration: p.o., daily, 13 weeks
Result: Reduced the number of infiltrating T cells, CD4 T cells, CD8 T cells, and CD4-CD8- double-negative (DN) T cells.
Decreased B cell counts.

化学信息

分子量 377.44
分子式 C19H30F3NO3
CAS No. 942399-20-4
别名 MT-1303

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础